UNDP, working in partnership with the Global Fund and national partners, has been successful in increasing the number of people on antiretroviral therapy from 360,000 people in 2010 to 1.1 million people in 2017.

Key results - HIV

UNDP has managed the implementation of Global Fund HIV, TB and Malaria grants in Zimbabwe since 2009, with the management of the TB and malaria grants since being transferred to the national government, as a result of a comprehensive approach to capacity development, implemented through collaboration between MOHCC, UNDP and the Global Fund. Read more... The AIDS epidemic in Zimbabwe is in decline with prevalence amongst males and females decreasing by 30% and 20% respectively between 2005 and 2015. Despite this, the prevalence of HIV remains among the highest in the world with 1.2 million people living with HIV (14.6% of people aged 15-64). Prevalence is higher amongst women, with the difference being most marked for younger age groups 20-34. Prevalence is also particularly high amongst sex workers. The HIV grant focuses on treatment and prevention, voluntary counselling and testing, and prevention of mother-to-child transmission (PMTCT). The UNDP-managed Global Fund investments have been instrumental in saving many lives. The number of people on antiretroviral therapy (ART) rose from 360,000 in 2010 to 1.1 million in 2017. This resulted in 87% of people living with HIV being on ART in 2015-6. Better health is central to human well-being and makes an important contribution to social and economic progress, as healthy populations live longer and are more productive. Life expectancy in Zimbabwe, which had declined since the 1980s to 41 years in 2003, subsequently increased to 61 years in 2015.

1.1 million people living with HIV currently on ART (2017)

Source: UNDP

People living with HIV on antiretroviral therapy (aged 15-64 in 2015-16)

Source: ZIMPHIA

393,000 deaths averted due to people being on ART between 2006 and 2016

Source: UNAIDS

Reducing the cost of HIV treatment

Price negotiations between UNDP and suppliers have achieved a landmark cost for ARVs of less than $75 per patient per year for the one-pill combination of the three HIV medicines known as TLE (Tenofovir, Lamivudine and Efavirenz). Because of this UNDP in 2017 was able to purchase 7.4 million packs of medicines for $46 Million USD for Zimbabwe – resulting in savings of over $29 Million USD compared to previous orders. So far procurement savings in Zimbabwe total $48 Million USD. With the help of these savings, the Ministry of Health and Child Care has now put over 1 million people on HIV treatment with support from the Global Fund, PEPFAR, DFID and UNDP.

Key results - Malaria

Malaria is a major public health problem and efforts have been focussed on enabling people to identify early symptoms, building the capacity of health workers, and procuring rapid diagnostic tests. Grant now transferred to the national government.

4.4 million insecticide treated bed nets distributed

Source: UNDP

Suspected cases tested (2016)

Source: World Health Organization

463,000 cases of Malaria treated

Source: UNDP

Key results - TB

Although Zimbabwe still carries a high burden of TB, UNDP supported programmes have contributed to decreases in both incidence and prevalence. Grant now transferred to the national government.

48,100 new smear positive TB cases detected and treated

Source: UNDP

Treatment success rate for new TB cases (2015)

Source: World Health Organization

72% of HIV positive TB patients on ART in (2015)

Source: World Health Organization

TB incidence rate per 100,000 population

Source: World Health Organization

Sarah's story

Theresa's story

Mortality Rates

Maternal Mortality

Source: World Health Organization

Infant mortality

Source: World Health Organization